Trevor L. Brasel, PhD

Assistant Professor, Department of Microbiology Immunology
Study Director, Regulated Studies, Institutional Office of Regulated Nonclinical Studies

Education:

Postdoctoral Fellowship
|2005| Lovelace Respiratory Research Institute, Albuquerque and The Research Centre for Toxicology and Hygienic Regulation of Biopreparations, Serpukhov, Russia

PhD in Medical Microbiology
|2004| Texas Tech University Health Sciences, Lubbock, TX

Bachelor of Science in Microbiology
|2000| Texas Tech University, Lubbock, TX

Overview:

Dr. Brasel has over seven years of regulatory science training and has served in some capacity on numerous in vitro and in vivo regulated studies in biocontainment (BSL-3 and BSL-4) ranging from challenge material production and characterization to antiviral efficacy studies in nonhuman primates. Dr. Brasel is well-versed in quality systems including model development, system qualifications and validations, study data management, and laboratory maintenance in context of GLP requirements. Dr. Brasel currently leads a team of technical personnel for regulated studies at UTMB and works in conjunction with the ORNcS Quality Assurance Unit. Dr. Brasel is a current member of the American Society for Microbiology. He has authored, co-authored, and/or lectured on over 65 articles, editorials, book chapters, poster and podium presentations, and panel discussions on topics ranging from undergraduate research to a broad range of microbiological topics including bioaerosol science and vaccine efficacy testing against select agents. In addition, he has aided in obtaining numerous grant- and contract-sponsored funds for conducting research in these fields.

Research Interests

Dr. Brasel’s interests lie in the strategic planning and execution of preclinical studies that evaluate medical countermeasures (vaccines and therapeutics) toward FDA licensure. He is currently focused on the implementation of quality systems and regulatory processes in A/BSL-4 laboratories. To date, no vaccines or therapeutics have been approved for human use against BSL-4 agents (e.g., Ebola and Marburg viruses). Through collaborations with world experts (many of whom reside at UTMB) in parallel with independently led studies. Dr. Brasel’s ultimate goal is FDA approval of high profile medical countermeasures specific for biodefense-related and emerging diseases.
Trevor L. Brasel, PhDtrbrasel@utmb.edu
Route 0184